The Chapman Lab focuses on modulating B lymphocytes—key adaptive immune cells responsible for antibody production—to improve outcomes in both infectious disease and autoimmunity.
Innovations in
B Lymphocyte Modulation
Antigen and Immunotherapy Engineering
Engineering B cells to boost immunity in infections and suppress autoimmunity through targeted therapies.
B cell Modulation using Targeted Therapeutics
Employing targeted therapies to boost vaccine-induced immunity and suppress autoimmunity by eliminating autoreactive B cells.
Germinal Center Biology
Investigating the molecular mechanisms driving humoral and autoimmunity
Advancing B Cell Therapeutics
Join the Team
The Chapman Lab opens January 2026 in Vanderbilt’s Department of Chemical and Biomolecular Engineering. We’re looking for enthusiastic, driven individuals excited to develop next-generation B cell therapeutics. Current openings include positions for lab technicians, graduate students, and postdoctoral researchers.
